We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
BioMarin Pharmaceutical announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) to the FDA for its investigational AAV5 gene therapy ...
US-based biotechnology company BioMarin Pharmaceutical has announced the completion of an underwritten public offering of senior subordinated convertible notes to raise $450m.